Identifying populations sensitive to environmental chemicals by simulating toxicokinetic variability.

The thousands of chemicals present in the environment (USGAO, 2013) must be triaged to identify priority chemicals for human health risk research. Most chemicals have little of the toxicokinetic (TK) data that are necessary for relating exposures to tissue concentrations that are believed to be toxic. Ongoing efforts have collected limited, in vitro TK data for a few hundred chemicals. These data have been combined with biomonitoring data to estimate an approximate margin between potential hazard and exposure. The most "at risk" 95th percentile of adults have been identified from simulated populations that are generated either using standard "average" adult human parameters or very specific cohorts such as Northern Europeans. To better reflect the modern U.S. population, we developed a population simulation using physiologies based on distributions of demographic and anthropometric quantities from the most recent U.S. Centers for Disease Control and Prevention National Health and Nutrition Examination Survey (NHANES) data. This allowed incorporation of inter-individual variability, including variability across relevant demographic subgroups. Variability was analyzed with a Monte Carlo approach that accounted for the correlation structure in physiological parameters. To identify portions of the U.S. population that are more at risk for specific chemicals, physiologic variability was incorporated within an open-source high-throughput (HT) TK modeling framework. We prioritized 50 chemicals based on estimates of both potential hazard and exposure. Potential hazard was estimated from in vitro HT screening assays (i.e., the Tox21 and ToxCast programs). Bioactive in vitro concentrations were extrapolated to doses that produce equivalent concentrations in body tissues using a reverse dosimetry approach in which generic TK models are parameterized with: 1) chemical-specific parameters derived from in vitro measurements and predicted from chemical structure; and 2) with physiological parameters for a virtual population. For risk-based prioritization of chemicals, predicted bioactive equivalent doses were compared to demographic-specific inferences of exposure rates that were based on NHANES urinary analyte biomonitoring data. The inclusion of NHANES-derived inter-individual variability decreased predicted bioactive equivalent doses by 12% on average for the total population when compared to previous methods. However, for some combinations of chemical and demographic groups the margin was reduced by as much as three quarters. This TK modeling framework allows targeted risk prioritization of chemicals for demographic groups of interest, including potentially sensitive life stages and subpopulations.

[1]  Amin Rostami-Hodjegan,et al.  Prediction of the Clearance of Eleven Drugs and Associated Variability in Neonates, Infants and Children , 2006, Clinical pharmacokinetics.

[2]  D. Hattis,et al.  Pharmacokinetic and Pharmacodynamic Factors That Can Affect Sensitivity to Neurotoxic Sequelae in Elderly Individuals , 2005, Environmental health perspectives.

[3]  Basic anatomical and physiological data for use in radiological protection: the skeleton. A report of a Task Group of Committee 2 of the International Commission on Radiological Protection. , 1995, Annals of the ICRP.

[4]  Amin Rostami-Hodjegan,et al.  Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model , 2011, Xenobiotica; the fate of foreign compounds in biological systems.

[5]  Vicki L Burt,et al.  National health and nutrition examination survey: sample design, 2011-2014. , 2014, Vital and health statistics. Series 2, Data evaluation and methods research.

[6]  Kevin McNally,et al.  PopGen: A virtual human population generator. , 2014, Toxicology.

[7]  Grant R. Wilkinson,et al.  A physiological approach to hepatic drug clearance , 1975 .

[8]  Wilfried De Backer,et al.  Body surface area in normal-weight, overweight, and obese adults. A comparison study. , 2006, Metabolism: clinical and experimental.

[9]  W. Slob,et al.  An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry , 2012, Critical reviews in toxicology.

[10]  Harvey J Clewell,et al.  Use of a Physiologically Based Pharmacokinetic Model to Identify Exposures Consistent With Human Biomonitoring Data for Chloroform , 2006, Journal of toxicology and environmental health. Part A.

[11]  Dion R. Brocks,et al.  Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery , 2008, Nature Reviews Drug Discovery.

[12]  G. L. Kedderis,et al.  Incorporating human interindividual biotransformation variance in health risk assessment. , 2002, The Science of the total environment.

[13]  H. McLeod,et al.  Genetic basis of drug metabolism. , 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[14]  K Rowland-Yeo,et al.  Prediction of in vivo drug clearance from in vitro data. II: Potential inter-ethnic differences , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[15]  R. Poland,et al.  Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: A cross‐ethnic comparative study , 2006, Clinical pharmacology and therapeutics.

[16]  D. Belle,et al.  Genetic factors in drug metabolism. , 2008, American family physician.

[17]  Y. Sugiyama,et al.  Inter-individual variability of in vivo CYP2D6 activity in different genotypes. , 2012, Drug metabolism and pharmacokinetics.

[18]  Ann M Richard,et al.  Linking high resolution mass spectrometry data with exposure and toxicity forecasts to advance high-throughput environmental monitoring. , 2016, Environment international.

[19]  Ruili Huang,et al.  Population-Based in Vitro Hazard and Concentration–Response Assessment of Chemicals: The 1000 Genomes High-Throughput Screening Study , 2015, Environmental health perspectives.

[20]  Shumei S. Guo,et al.  2000 CDC Growth Charts for the United States: methods and development. , 2002, Vital and health statistics. Series 11, Data from the National Health Survey.

[21]  Z H Israili,et al.  HUMAN ALPHA-1-GLYCOPROTEIN AND ITS INTERACTIONS WITH DRUGS†,‡ , 2001, Drug metabolism reviews.

[22]  John C Lipscomb,et al.  Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment , 2001, Toxicology and industrial health.

[23]  Thomas Lumley,et al.  Analysis of Complex Survey Samples , 2004 .

[24]  L Zhang,et al.  The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies , 2008, Clinical pharmacology and therapeutics.

[25]  P. Prusis,et al.  Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds , 2010, Xenobiotica; the fate of foreign compounds in biological systems.

[26]  M. Jamei,et al.  A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. , 2009, Drug metabolism and pharmacokinetics.

[27]  M. Hiratsuka In vitro assessment of the allelic variants of cytochrome P450. , 2012, Drug metabolism and pharmacokinetics.

[28]  J. Valentin Basic anatomical and physiological data for use in radiological protection: reference values , 2002, Annals of the ICRP.

[29]  D. Hattis,et al.  Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[30]  Lester R Curtin,et al.  National health and nutrition examination survey: analytic guidelines, 1999-2010. , 2013, Vital and health statistics. Series 2, Data evaluation and methods research.

[31]  Paul S Price,et al.  Modeling Interindividual Variation in Physiological Factors Used in PBPK Models of Humans , 2003, Critical reviews in toxicology.

[32]  Paola Annoni,et al.  Variance based sensitivity analysis of model output. Design and estimator for the total sensitivity index , 2010, Comput. Phys. Commun..

[33]  J. Shepherd,et al.  Total body bone area, bone mineral content, and bone mineral density for individuals aged 8 years and over: United States, 1999-2006. , 2013, Vital and health statistics. Series 11, Data from the National Health Survey.

[34]  Franco Lombardo,et al.  Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds , 2008, Drug Metabolism and Disposition.

[35]  Robert G. Pearce,et al.  httk: R Package for High-Throughput Toxicokinetics. , 2017, Journal of statistical software.

[36]  G. Schwartz,et al.  Measurement and estimation of GFR in children and adolescents. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[37]  K. Neville,et al.  Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. , 2006, The oncologist.

[38]  Harvey J. Clewell,et al.  Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.

[39]  Y. Sugiyama,et al.  Prediction of interindividual variability in pharmacokinetics for CYP3A4 substrates in humans. , 2010, Drug metabolism and pharmacokinetics.

[40]  R. Barr,et al.  Age- and gender-dependent values of skeletal muscle mass in healthy children and adolescents , 2011, Journal of cachexia, sarcopenia and muscle.

[41]  Imran Shah,et al.  Toxicokinetic Triage for Environmental Chemicals. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[42]  G. Tucker,et al.  Incorporation of Inter-Individual Variability into the Prediction of In Vivo Drug Clearance from In Vitro Data , 2006 .

[43]  Dean P. Jones,et al.  High-performance metabolic profiling of plasma from seven mammalian species for simultaneous environmental chemical surveillance and bioeffect monitoring. , 2012, Toxicology.

[44]  David M. Reif,et al.  High-throughput models for exposure-based chemical prioritization in the ExpoCast project. , 2013, Environmental science & technology.

[45]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[46]  R. Judson,et al.  High throughput heuristics for prioritizing human exposure to environmental chemicals. , 2014, Environmental science & technology.

[47]  P. Routledge The plasma protein binding of basic drugs. , 1986, British journal of clinical pharmacology.

[48]  John C Lipscomb,et al.  Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. , 2007, Current drug metabolism.

[49]  Arnaud Tonnelier,et al.  Screening of chemicals for human bioaccumulative potential with a physiologically based toxicokinetic model , 2011, Archives of Toxicology.

[50]  K. Flegal,et al.  Prevalence of childhood and adult obesity in the United States, 2011-2012. , 2014, JAMA.

[51]  Robert J Kavlock,et al.  Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[52]  Harvey J Clewell,et al.  Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling , 2007, Journal of Exposure Science and Environmental Epidemiology.

[53]  I. Ijiri,et al.  A statistical analysis of the internal organ weights of normal Japanese people. , 1997, Health physics.

[54]  G R Wilkinson,et al.  Commentary: a physiological approach to hepatic drug clearance. , 1975, Clinical pharmacology and therapeutics.

[55]  W. Slikker,et al.  Incorporating children's toxicokinetics into a risk framework. , 2004, Environmental health perspectives.

[56]  Melvin E. Andersen,et al.  Incorporating New Technologies Into Toxicity Testing and Risk Assessment: Moving From 21st Century Vision to a Data-Driven Framework , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[57]  L. Grummer-Strawn,et al.  Use of World Health Organization and CDC Growth Charts for Children Aged 0–59 Months in the United States (Excerpt) , 2010, Clinical Lactation.

[58]  David M. Reif,et al.  Update on EPA's ToxCast program: providing high throughput decision support tools for chemical risk management. , 2012, Chemical research in toxicology.

[59]  R. Judson,et al.  Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment. , 2011, Chemical research in toxicology.

[60]  Kairui Feng,et al.  The Simcyp population-based ADME simulator. , 2009, Expert opinion on drug metabolism & toxicology.

[61]  Walter Schmitt,et al.  Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[62]  T. Mizutani PM Frequencies of Major CYPs in Asians and Caucasians , 2003, Drug metabolism reviews.

[63]  Melvin E. Andersen,et al.  Incorporating High-Throughput Exposure Predictions With Dosimetry-Adjusted In Vitro Bioactivity to Inform Chemical Toxicity Testing , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[64]  R. Hines,et al.  Ontogeny of human hepatic cytochromes P450 , 2007, Journal of biochemical and molecular toxicology.

[65]  Weimin Sun,et al.  Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory , 2011, Genetics in Medicine.

[66]  Robert J Kavlock,et al.  Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[67]  Kristin Isaacs,et al.  Estimating Sobol sensitivity indices using correlations , 2012, Environ. Model. Softw..

[68]  Julien Jacques,et al.  Sensitivity analysis in presence of model uncertainty and correlated inputs , 2006, Reliab. Eng. Syst. Saf..

[69]  J. Lipscomb,et al.  Covariation of Human Microsomal Protein Per Gram of Liver with Age: Absence of Influence of Operator and Sample Storage May Justify Interlaboratory Data Pooling , 2008, Drug Metabolism and Disposition.

[70]  Walter Schmitt,et al.  General approach for the calculation of tissue to plasma partition coefficients. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.

[71]  H. Pan,et al.  WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age , 2006 .

[72]  G. Schwartz,et al.  Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. , 1978, The Journal of pediatrics.

[73]  L. Teuschler,et al.  Variance of Microsomal Protein and Cytochrome P450 2E1 and 3A Forms in Adult Human Liver , 2003, Toxicology mechanisms and methods.

[74]  Sean M Hays,et al.  Consideration of dosimetry in evaluation of ToxCast™ data , 2011, Journal of applied toxicology : JAT.

[75]  D. Bailey,et al.  Bone mineral accrual from 8 to 30 years of age: An estimation of peak bone mass , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[76]  Y. Sugiyama,et al.  Prediction of inter-individual variability in the pharmacokinetics of CYP2C19 substrates in humans. , 2014, Drug metabolism and pharmacokinetics.

[77]  W. Koo,et al.  Body composition in human infants at birth and postnatally. , 2000, The Journal of nutrition.